P
ostoperative supraventricular tachyarrhythmias are a frequent complication in surgical intensive care unit (ICU) patients. New-onset supraventricular tachyarrhythmias (SVT) have been reported to occur in 10% to 29% of patients after major noncardiac surgery and in up to 64% of patients after cardiac surgery (1) (2) (3) . Development of postoperative SVT is associated with increased patient morbidity and mortality, prolonged ICU and hospital stay, as well as significantly increased costs of care (1, 4) . In a mixed surgical patient population, we reported SVT to occur in approximately 15% of patients (4) . In the majority of these patients, SVT led to deterioration in hemodynamics, usually due to a significant decrease in cardiac index necessitating either initiation or an increase in vasopressor and/or inotropic therapy. Cardiac surgery patients with SVT stayed approximately 6 days longer in the ICU than control patients without tachyarrhythmia. Although none of the patients died as a direct consequence of arrhythmia, the occurrence of SVT was associated with a three-fold increase in ICU mortality (4) .
It may be suggested that rapid and successful termination of new-onset SVT could favorably influence morbidity and mortality of ICU patients and thus significantly decrease costs of care.
Direct current cardioversion is known to be a highly effective therapy for terminating SVT and restoring sinus rhythm in medical patients (5) . In the postoperative period, direct-current cardioversion (DCC) has been suggested as a first-line therapy for SVT of acute onset, especially in patients with deteriorating hemodynamics (6 -8) . In contrast to drug therapy, DCC should be rapid acting and devoid of major complications that have been associated with different drug therapies (6) . Unfortunately, prospective investigations on the success rate of DCC in surgical patients and, in particular, in the ICU are still lacking. In addition, our clinical experience concerning effectiveness of DCC during the last years has been disappointing. Therefore, we prospectively investigated the effectiveness of DCC for termination of new-onset SVT in 37 consecutive surgical ICU patients without history of tachyarrhythmias.
MATERIALS AND METHODS
The study protocol was approved by the ethical committee of the Leopold Franzens University of Innsbruck. We prospectively evaluated the effectiveness of DCC in 37 consecutive surgical ICU patients with new-onset SVT admitted to a 12-bed surgical ICU between March 1, 1999 and December 31, 1999 . Patients included in this study were treated after major abdominal (n ϭ 13), cardiac (n ϭ 13), vascular (n ϭ 1), trauma (n ϭ 4), orthopedic (n ϭ 3), and thoracic surgery (n ϭ 2). One patient was admitted because of pneumonia 1 wk after surgery.
SVT were defined as narrow-complex, nonsinus tachycardias with heart rate Ͼ100 beats/ min for at least 15 mins. Patients with prior antiarrhythmic therapy except ␤-adrenergic receptor blocking agents and cardiac glycosides, patients with a history of atrial fibrillation/flutter and/or paroxysmal SVT, presence of hypokalemia (K ϩ Ͻ3.5 mmol/L), hypomagnesemia (Mg 2ϩ Ͻ0.7 mmol/L), or hypoxia (PaO 2 Ͻ60 torr [7. 98 kPa]) were excluded from the study. ␤-Adreneric receptor blocking agents (n ϭ 4) were continued during the perioperative period. In patients receiving medication with cardiac glycosides (n ϭ 4), serum levels of digoxin or digitoxin were determined before DCC.
Before DCC, a 12-lead electrocardiogram, arterial blood gas, and serum electrolyte analysis (Na ϩ , K ϩ , Ca 2ϩ , and Mg 2ϩ ) were obtained in all patients. Mean arterial pressure and central venous pressure were invasively monitored, and values were recorded immediately before DCC. Serial creatine kinase-MB isoenzyme determinations (three times within 24 hrs) were performed. Demographic data including age, sex, weight, and surgical region were collected. Presence of coronary artery disease, congestive heart failure, hypertension, diabetes, preexisting renal insufficiency, and chronic obstructive pulmonary disease was recorded in a binary fashion (0 ϭ absence of disease; 1 ϭ disease present).
The Simplified Acute Physiologic Score was calculated from worst physiologic data obtained within the first 24 hrs after ICU admission or before onset of SVT in patients developing SVT within the first 24 hrs (9). A multiple organ dysfunction syndrome score was calculated from worst physiologic data before onset of SVT (10) . Patients were evaluated for presence or absence of the clinically defined systemic inflammatory response syndrome (SIRS) with or without systemic infection, specifically during the 24 hrs before onset of SVT (11) . Catecholamine and/or phosphodiesterase-inhibitor therapy immediately before onset of SVT was recorded in a binary fashion (0 ϭ absence of therapy or therapy with dopamine Ͻ5 g/kg/min; 1 ϭ presence of catecholamine-and/or phosphodiesterase-inhibitor therapy).
DCC was performed using a Cardioserv 4.1 defibrillator (Marquette Hellige Medical Systems, Freiburg, Germany). Alert patients were sedated with 0.2 to 0.4 mg/kg of etomidate for DCC. To optimize electrical conductivity, gelcoated defi pads (Nikman DP-700 defi pads, Maersk Medical, Stonehouse, UK) with a diameter of 15 cm were placed in the right infraclavicular area adjacent to the sternum and over the apex of the heart. In women, the apex defi pad was placed under the left breast. Two standard hand-held electrodes with a diameter of 10 cm were firmly attached against the defi pads. In patients with regular SVT, a maximum of four consecutive cardioversions with energy delivery of 50, 100, 200, and 300 J were performed, whereas in patients with irregular SVT, cardioversion was done with energy delivery of 100, 200, and 360 J. Time between consecutive DCC attempts was 3 mins. DCC was performed at end-expiration. Primary success of DCC was defined as restoration of sinus rhythm (SR) for at least 5 mins. A 12-lead electrocardiogram was repeated after DCC and at 1, 24, and 48 hrs after successful DCC. In patients not responding to DCC or in patients with recurrent SVT, antiarrhythmic therapy with class III antiarrhythmic drugs was started according to our institutional routine.
Statistical Analysis. As a primary study end point, therapeutic effectiveness of DCC was followed for 48 hrs. Patients were divided according to primary success into primary responders and nonresponders. To estimate success rate, Clopper-Pearson 95% confidence intervals (CI) were calculated. As secondary study end points, demographic, premorbidity, laboratory data, presence or absence of SIRS with or without systemic infection, presence or absence of catecholamine, and/or phosphodiesterase-inhibitor therapy immediately before onset of SVT of primary responders and nonresponders were compared using chisquare test, Fisher's exact test, or KruskalWallis one-way analysis of variance, as appropriate; p Ͻ 0.05 was considered statistically significant. Data are presented as median values and range.
RESULTS
During the study period, DCC was performed in 37 consecutive surgical ICU patients with a median age of 72 yrs (range, 34 -94 yrs). Eight of 37 patients (22%) studied died in the ICU. Thirty-one patients (84%) presented with atrial fibrillation with a rapid ventricular response, and six patients (16%) showed regular narrow-complex, nonsinus tachycardia. In patients on cardiac glycoside medication (n ϭ 4), digoxin and digitoxin plasma concentrations were within therapeutic limits before DCC.
Age, body mass index, sex, occurrence of SIRS with and without systemic infection, presence of catecholamine and/or phosphodiesterase-inhibitor therapy, premorbidity, hemodynamic data, time from ICU admission to onset of SVT, electrolytes, arterial blood gas analysis at onset of SVT, and maximum creatine kinase-MB isoenzyme values within 24 hrs from all patients, primary responders, and nonresponders are presented in Table  1 . Primary responders were significantly younger than nonresponders. There were no statistically significant differences in sex, body mass index, Simplified Acute Physiologic Score, occurrence of SIRS with and without systemic infection, multiple organ dysfunction syndrome score, premorbidity data, and time from ICU admission to onset of SVT.
Most patients were already hemodynamically unstable before onset of SVT. Eight patients received no pharmacologic cardiovascular support (n ϭ 5) or only dopamine Ͻ5 g/kg/min (n ϭ 3). Thirteen patients were infused with a combination of at least two catecholamines consisting of dopamine Ͼ5 g/kg/min, epinephrine, phenylephrine, or norepinephrine with or without the phosphodiesterase-inhibitor milrinone. Sixteen patients received one catecholamine (dopamine Ͼ5 g/kg/min, epinephrine, phenylephrine, or norepinephrine) or the phosphodiesterase-inhibitor milrinone. There were no differences in the number of patients treated with catecholamines and/or phosphodiesterase-inhibitors between groups.
There were no differences in hemodynamic variables, sodium, potassium, magnesium, maximum creatine kinase-MB isoenzyme concentrations, arterial pH, and carbone dioxide tension between groups. However, primary responders had significantly higher ionized calcium concentrations and arterial oxygen tension before DCC.
Therapeutic success of DCC through 48 hrs is shown in Figure 1 . Thirteen patients (35%; 95% CI, 20 -53%) primarily responded to DCC with restoration of SR, of which eight patients remained in SR (24%; CI, 12-41%) at 1 hr. At 24 and 48 hrs, six (16%; CI, 6 -32%) and five (13.5%; CI, 5-29%) patients were in SR, respectively. Table 2 presents the number of DCC shocks delivered and primary success of DCC in patients with regular and irregu-lar SVT. Eight patients developed sinus rhythm in response to the first DCC shock and four patients to the second DCC shock. One of 22 patients converted into sinus rhythm after three DCC maneuvers, whereas no patient responded to a fourth DCC shock.
DISCUSSION
This is the first prospective study on efficacy of DCC for acute treatment of new-onset SVT in a mixed surgical ICU patient population. Despite an initial success rate, arbitrarily defined as restoration of SR for at least 5 mins, of 35%, only 16% and 13.5% of patients remained in SR at 24 and 48 hrs, respectively. These results are in striking contrast to current recommendations suggesting that DCC is an efficient first-line therapy for treatment of SVT in the surgical ICU (6, 7) .
In medical patients, DCC is reported to be highly effective in terminating SVT of recent onset, particularly atrial fibrillation with rapid ventricular rate (5). Aberg and Cullhed (12) reported a success rate of 81% in one study involving 181 patients with atrial fibrillation. In a more recent study, Arnar and Danielsen (13) reported that DCC restored SR in 77% of patients with new-onset atrial fibrillation or flutter. Interestingly, the primary success rate was not influenced by heart size on chest radiograph or echocardiographic variables, e.g., left atrial size, but these variables predicted recurrence of SVT during a follow-up period of 1 yr.
Surgical ICU patients included in this study should have had ideal preconditions for electrical restoration of SR. Patients with history of SVT before surgery were excluded. None of the patients experienced hypokalemia, hypomagnesemia, or hypoxemia before onset of SVT. One might speculate that substantial differences in trigger mechanisms and pathophysiology responsible for development of SVT between surgical and medical patients may account for the inefficiency of DCC to restore sinus rhythm in these patients.
The perioperative neurohormonal stress response with loss of vagal tone and activation of the sympathoadrenergic as well as renin-angiotensin system is a unique pathophysiological condition in surgical ICU patients and may well be involved in the onset and perpetuation of SVT. Kalman et al. (14) reported elevated postoperative norepinephrine levels to be independently associated with the occurrence of atrial fibrillation in patients after coronary artery bypass grafting, suggesting that sympathetic activation may be important in the pathogenesis of postoperative SVT. In a recent investigation, we found severity of cardiovascular failure assessed by the extent of catecholamine support necessary to achieve hemodynamic stability to be an independent predictor for development of postoperative tachyarrhythmias in cardiac surgery patients, indicating a strong causal relationship between catecholamine therapy and development of SVT (15) . In the present study, 29 patients (78%) received catecholamine and/or phosphodiesteraseinhibitor therapy at onset of SVT. Endogenous and additional exogenous catecholamine loads may not only be a major pathogenic factor for development of postoperative SVT, but may also have an important influence on success rate of antiarrhythmic therapies, such as DCC.
SIRS with and without systemic infection is a common finding in surgical ICU patients developing new-onset SVT (16) . In contrast, systemic inflammation is usually absent in medical patients who are studied for effectiveness of DCC. In previous studies, we have demonstrated SIRS with and without systemic infection to be an independent predictor for subsequent development of tachyarrhythmias. Presence of SIRS with and without systemic infection increased the risk by approximately 36 times (4) . Similarly, Brathwaite and Weissmann (1) reported that 15% of patients with new-onset SVT died because of sepsis, whereas in a control group, sepsis accounted for only 3% of deaths. A recent investigation in cardiac surgery patients described a significant association between postoperative acute-phase response and development of tachyarrhythmias (17) . In the present study, 24 patients (65%) fulfilled clinical criteria of SIRS with and without systemic infection before onset of SVT. Although the exact pathophysiological correlation between systemic inflammation and development of tachyarrhythmias is not yet clear, systemic inflammation could adversely affect success rate of DCC in surgical ICU patients.
Primary responders to DCC were significantly younger than nonresponders. This finding is in line with studies from medical patients. Van Gelder and Crijns (18) reported that in patients with atrial fibrillation, the success rate of DCC was higher in younger patients compared with older patients. In addition, primary success rate was independently predicted by younger age (19) .
An unexpected finding was a significant difference in ionized blood calcium concentrations between primary responders and nonresponders. Hypocalcemia causes QT c prolongation and, thus, may result in early afterdepolarization and triggered arrhythmias, in particular torsades de pointes. However, an association between low ionized calcium concentration and development of SVT or response to therapeutic maneuvers is much less clear and may well represent a finding by chance. Similarly, we observed higher arterial PO 2 values in primary responders compared with nonresponders. However, none of the nonresponders experienced clinical hypoxia defined as PaO 2 Ͻ60 torr (7.98 kPa). Most patients presented with PaO 2 values Ͼ70 torr (9.1 kPa).
DCC was performed according to a standardized protocol used in our institution. Energy levels applied were 50, 100, 200, and 300 J for regular SVT and 100, 200, and 360 J for treatment of irregular SVT. For patients with atrial flutter, Pinski et al. (20) reported that DCC with 100 J will restore SR in 85% of patients. Ewy (21) advocates an initial energy of 200 J for treatment of atrial fibrillation. In a small series of medical patients with atrial fibrillation, delivery of 720 J using two synchronized external defibrillators has been reported to restore SR in 84% of patients who are not responding to conventional DCC (22) . Unfortunately, optimal energy settings for treatment of SVT have not been evaluated in a large series of patients.
We used the apex-lateral paddle position for DCC. This paddle position is reported to result in a slightly increased transthoracic resistance compared with the anteroposterior position. However, Kerber et al. (23) observed no differences in DCC success when comparing both paddle positions. These findings have been confirmed by Dalzell et al. (24) , who showed a constant success rate independent of paddle position in medical patients. We used a monophasic defibrillator generating a damped sinus-wave impulse for DCC. Recently, synchronizable biphasic defibrillators have become commercially available, and, in small studies, biphasic shock forms have been shown to be more efficient in terminating ventricular tachycardias than monophasic shock forms. To the best of our knowledge, only one study comparing both types of shock forms for cardioversion of SVT showed higher success rates for biphasic shock forms for transthoracic cardioversion of atrial fibrillation in general medical patients (25) .
Limitations of the Study. Most patients investigated presented with atrial fibrillation with a rapid ventricular response, whereas only six patients developed regular SVT. One of these patients had atrial flutter with 2:1 AV block, and five patients presented with paroxysmal SVT. Therefore, conclusions regarding effectiveness of DCC for treatment of regular SVT can only be drawn with caution. One might speculate that in patients with paroxysmal SVT, administration of adenosine might have been a more appropriate initial treatment, in particular in patients with AV nodal reentry tachycardia compared with DCC. Unfortunately, in clinical practice, it is very difficult to differentiate between subtypes of paroxysmal SVT, e.g., AV nodal reentry or junctional tachycardia at the bedside (26) . Concerning the occurrence of AV nodal reentry tachycardia, Artucio and Pereira (2) reported that AV nodal reentry tachycardia represented a rare event (5%) in a prospective observational study including 2820 surgical and medical intensive care patients. In addition, a preliminary report by Kirton et al. (27) suggested that adenosine has only marginal efficacy in the treatment of new-onset AV nodal reentry 8  3  5  8  0  2  4  0  4  4  0  3  22  0  22  1  21  4  3  3  0  0  3 SVT, supraventricular tachyarrhythmias.
tachycardia in critically ill surgical or trauma patients. However, Heinz (26) pointed out that for correct diagnosis of AV nodal reentry tachycardia complex, an electrophysiological workup, which is usually not available in the ICU setting, would be necessary. According to our institutional routine, DCC for regular SVT was performed four times and terminated with maximum energy levels of 300 J. Therefore, we cannot exclude the possibility of successful DCC at higher energy levels, e.g., 360 J. Interestingly, most patients primarily responding to DCC demonstrated restoration of sinus rhythm within the first two DCC maneuvers, irrespective of presence of irregular or regular rhythm (Table 2 ). Only one of 25 patients requiring more than two DCC shocks converted to sinus rhythm. Therefore, it seems unlikely that the application of higher energy levels may have significantly influenced the presented results.
In conclusion, in surgical ICU patients, DCC is an ineffective therapeutic method for successful long-term termination of new-onset SVT, in particular, atrial fibrillation with a rapid ventricular response. We speculate that varying therapeutic effectiveness between medical patients and surgical ICU patients may result from the major differences in the primary trigger mechanisms responsible for the development of SVT. In particular, high endogenous and exogenous catecholamine loads and, probably, presence of systemic inflammation may prevent therapeutic success of DCC. The optimal therapeutic regimen for effective and rapid termination of new-onset SVT in surgical ICU patients still remains to be established. 
